IGFBP2 and glioma: In human glioma, the insulin-like growth factor binding protein-2 (IGFBP2), circulating in the serum of patients or endogenously produced by the tumor, activates ERK1/2 and determines resistance to temozolomide by favoring the entrance into S- and G2/M-phases [28].